Breast Cancer
News
EMILIA Confirms T-DM1 Overall Survival Advantage
Major Finding: Median overall survival was 30.9 months for T-DM1 and 25.1 months for capecitabine plus lapatinib (hazard ratio = 0.68, P = .0006)....
News
One Year of Trastuzumab Remains the Standard in Early Breast Cancer
Major Findings: The hazard ratios for disease-free and overall survival comparing 1 year and 2 years of adjuvant trastuzumab in the HERA trial...
News
California Enacts Breast Density Notification Law
Conference Coverage
Everolimus Reduces Breast Cancer Treatment Effects in Bone
Major Finding: Treatment with everolimus and exemestane was associated with improved levels of bone-specific alkaline phosphatase, amino-terminal...
News
FDA Approves Ultrasound Screening of Dense Breasts
News
EMILIA Study: T-DMI Prolongs Progression-Free and Overall Survival
Major Finding: The median progression-free survival among those randomized to receive trastuzumab emtansine was 9.6 months, compared with 6.4...
News
Evidence Mounts on Heart Failure After Trastuzumab in Breast Cancer Survivors
Major Finding: The adjusted risk of heart failure (HF) and/or cardiomyopathy increased fourfold among women who received trastuzumab alone and...
News
Breast Cancer Chemoprevention: Hit It Harder
News
Dense Breasts Don't Increase Risk of Breast Cancer Death
News
Prior Thoracic Radiotherapy Warrants Annual Breast MRI
News
Ovarian Cortex Autografts in Cancer Survivors Yield Live Births
Major Finding: Sixteen pregnancies and three live births have occurred, some following in vitro fertilization and some following natural...